Early response to desipramine among women with bulimia nervosa

Objective Numerous trials have demonstrated the efficacy of antidepressant medications for the treatment of bulimia nervosa (BN). The current study examined whether early response to medication predicted response to medication at the end of a controlled trial. Method Data from two previously publish...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of eating disorders 2006, Vol.39 (1), p.72-75
Main Authors: Walsh, B.T, Sysko, R, Parides, M.K
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
antidepressant medication
Antidepressants
Antidepressive Agents, Tricyclic - therapeutic use
Biological and medical sciences
Body Mass Index
Bulimia
bulimia nervosa
Bulimia Nervosa - drug therapy
Bulimia Nervosa - psychology
depression
desipramine
Desipramine - therapeutic use
Drug therapy
early treatment
Eating behavior disorders
Eating disorders
Female
Humans
Medical sciences
medical treatment
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
receiver operating characteristic curves
Time Factors
Treatment Outcome
Women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Numerous trials have demonstrated the efficacy of antidepressant medications for the treatment of bulimia nervosa (BN). The current study examined whether early response to medication predicted response to medication at the end of a controlled trial. Method Data from two previously published studies of desipramine (DMI) were used. Seventy-seven patients with BN were included in the analysis. Receiver operating characteristic (ROC) curves were constructed to examine the relation between the percentage reduction in symptoms at each week and failure to respond to antidepressant medication at the end of the trial. Results Eventual nonresponders to DMI could be reliably identified in the first 2 weeks of treatment. Conclusion The current study provides preliminary evidence that patients with BN who will not respond to antidepressant medication can be identified in the first 2 weeks of treatment.
ISSN:0276-3478
1098-108X
DOI:10.1002/eat.20209